Výsledky vyhledávání - "Brendan Lichtenthal"

Taxane anticancer agents: a patent perspective

Autor: Iwao Ojima, Changwei Wang, Xin Wang, Siyeon Lee, Brendan Lichtenthal

Publikováno v: Expert opinion on therapeutic patents. 26(1)

Paclitaxel and docetaxel were two epoch-making anticancer drugs and have been successfully used in chemotherapy for a variety of cancer types. In the year 2010, a new taxane, cabazitaxel, was approved by FDA for use in combination with prednisone for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a377446c3df5f680135a421e8e70467
https://pubmed.ncbi.nlm.nih.gov/26651178

Zobrazit plný text záznamu

Design, Synthesis and Application of Fluorine-Labeled Taxoids as 19F NMR Probes for the Metabolic Stability Assessment of Tumor-Targeted Drug Delivery Systems

Autor: Brendan Lichtenthal, Jonathan F. Khan, Jacob G. Vineberg, Joshua D. Seitz, Longfei Wei, Chi-Feng Lin, Iwao Ojima

Novel tumor-targeting drug conjugates, BLT-F2 (1) and BLT-S-F6 (2), bearing a fluorotaxoid as the warhead, a mechanism-based self-immolative disulfide linker, and biotin as the tumor-targeting module, were designed and synthesized as 19F NMR probes.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba63700ff355068d317789bc8057cc53
https://europepmc.org/articles/PMC4337250/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání